Developing a new method for delivering cancer vaccines
Controlled Antigen Delivery for Prophylactic Cancer Vaccination
This study is testing a new way to deliver cancer treatments directly to tumors using a special gel, which could make the treatments work better and cause fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11088942 on NIH RePORTER |
What this research studies
This research focuses on creating a peptide-based hydrogel platform that allows for the targeted delivery of cancer treatments directly to tumors. By using this innovative approach, the goal is to enhance the effectiveness of existing cancer therapies while reducing harmful side effects that often affect patients' quality of life. The study aims to utilize boronic acid-containing small molecule drugs, which have shown promise in treating certain cancers, and deliver them locally to maximize their impact. Patients may benefit from a more effective treatment with fewer systemic toxicities.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with solid tumors and may benefit from localized cancer therapies.
Not a fit: Patients with cancers that are not solid tumors or those who are not eligible for localized treatment approaches may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with reduced side effects for patients.
How similar studies have performed: Previous research has shown promise in using localized drug delivery systems for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Pogostin, Brett — Massachusetts Institute of Technology
- Study coordinator: Pogostin, Brett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.